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SARM1 acts downstream of neuroinflammatory and
necroptotic signaling to induce axon degeneration
Kwang Woo Ko1, Jeffrey Milbrandt2,3, and Aaron DiAntonio1,3
Neuroinflammation and necroptosis are major contributors to neurodegenerative disease, and axon dysfunction and
degeneration is often an initiating event. SARM1 is the central executioner of pathological axon degeneration. Here, we
demonstrate functional and mechanistic links among these three pro-degenerative processes. In a neuroinflammatory model
of glaucoma, TNF-α induces SARM1-dependent axon degeneration, oligodendrocyte loss, and subsequent retinal ganglion cell
death. TNF-α also triggers SARM1-dependent axon degeneration in sensory neurons via a noncanonical necroptotic signaling
mechanism. MLKL is the final executioner of canonical necroptosis; however, in axonal necroptosis, MLKL does not directly
trigger degeneration. Instead, MLKL induces loss of the axon survival factors NMNAT2 and STMN2 to activate SARM1 NADase
activity, which leads to calcium influx and axon degeneration. Hence, these findings define a specialized form of axonal
necroptosis. The demonstration that neuroinflammatory signals and necroptosis can act locally in the axon to stimulate
SARM1-dependent axon degeneration identifies a therapeutically targetable mechanism by which neuroinflammation can
stimulate axon loss in neurodegenerative disease.
Introduction
While there are many different causes of neurodegenerative
diseases, targeting common mechanisms promoting neuro-
nal dysfunction and death would be a powerful approach for
treating these devastating disorders. Early efforts to identify a
common mechanism focused on neuronal apoptosis in hopes of
blocking neuronal cell death. While tremendous strides were
made in delineating the molecular mechanisms of apoptosis in
neurons, targeting this pathway has not generated new treat-
ments for neurodegeneration (Mattson, 2000; Maino et al.,
2017). There are multiple reasons for this failure. First, we
now know that there are many other cell death pathways that
can kill neurons (Fuchs and Steller, 2015). Indeed, necroptosis
is now appreciated to be a druggable pathway of programmed
necrosis that is a very exciting target in many neurodegener-
ative diseases (Zhang et al., 2017; Yuan et al., 2019). Second,
neurodegenerative diseases activate not only cell death path-
ways but also axonal death programs (Simon and Watkins,
2018). As synapse and axon loss is an early event in many
neurodegenerative disorders (Coleman and Höke, 2020),
mechanisms to maintain neuronal connectivity may need to be
integrated with approaches for blocking neuronal cell death in
order to maintain a functional nervous system. Finally, neurons
are not the only cells affected in neurodegenerative diseases. In
fact, neuroinflammation and microglial function is a central
driver of many neurodegenerative diseases (Hickman et al.,
2018; Perry and Holmes, 2014). Using both an in vivo glau-
coma model and an in vitro neuronal culture model, we now
explore functional andmolecular links among neuroinflammatory
signaling, necroptosis, and axonal degeneration.
Glaucoma is a neurodegenerative disease of retinal gan-
glion cells (RGCs) and a major preventable cause of blindness
(Weinreb et al., 2014). While increases in intraocular pressure
(IOP) are the proximate cause of most cases of glaucoma, neu-
roinflammation is a major contributor to the pathogenesis of
glaucoma. Indeed, glaucoma can develop in the absence of IOP,
and neurodegeneration can proceed even after successful res-
toration of normal pressures (Beidoe and Mousa, 2012). In both
patients and rodent models, TNF-α is up-regulated in glauco-
matous eyes (Yan et al., 2000; Sawada et al., 2010; Tezel et al.,
2001). In experimental models, TNF-α is sufficient to activate
microglia, stimulating a positive feedback loop that is capable of
inducing RGC axon loss and eventual cell death (Nakazawa et al.,
2006; Roh et al., 2012). Here, we used this neuroinflammatory
model of glaucoma to test the hypothesis that SARM1 (sterile
alpha and TIR motif 1), the central executioner of pathological
axon degeneration, contributes to the pathogenesis of glaucoma.
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SARM1 is an inducible NAD+ cleavage enzyme whose ac-
tivation triggers metabolic catastrophe and axon degenera-
tion in both classic injury-induced Wallerian degeneration
and the dying back axon loss of peripheral neuropathy
(Gerdts et al., 2016; Geisler et al., 2016; Essuman et al., 2017).
Following optic nerve crush, SARM1 is required for distal RGC
axon degeneration, but is not necessary for injury-dependent
apoptosis and RGC death (Fernandes et al., 2018). While it is
clear that SARM1 functions in RGCs to promote Wallerian
degeneration, whether it acts in more disease-relevant mod-
els of RGC death is unknown. Overexpression of the fusion
protein Wlds, which includes the NAD+ biosynthetic enzyme
NMNAT1 (nicotinamide nucleotide adenylyltransferase 1) and
so can inhibit SARM1 (Sasaki et al., 2016), has given con-
flicting results in glaucoma models. Wlds can protect axons
but not cell bodies in a rat glaucoma model (Beirowski et al.,
2008), while the coadministration of the NAD+ precursor
nicotinamide in conjunction with Wlds (Williams et al., 2017a)
or the overexpression of cytosolically targeted NMNAT1 en-
zyme (Zhu et al., 2013) can protect axons and cell bodies.
Whether NMNAT1/Wlds is primarily augmenting NAD+ bio-
synthesis or inhibiting SARM1 in these paradigms is un-
known. Hence, it is important to test the requirement for
SARM1 directly in a glaucoma model, in particular because
SARM1 is an enzyme and so a druggable target (DiAntonio,
2019). Finally, mechanisms of SARM1 activation are well
understood in Wallerian degeneration, where axotomy blocks
delivery of labile axon survival factors that inhibit SARM1
(Figley and DiAntonio, 2020). However, whether and how
other disease processes activate SARM1 are not known.
Here, we test the role of SARM1 in a neuroinflammatory
model of glaucoma, demonstrating that SARM1 is required for
RGC axon loss, RGC death, and oligodendrocyte death following
intravitreal TNF-α application. We show that oligodendrocyte
death is secondary to axon loss in this glaucoma model using a
therapeutically translatable adeno-associated virus (AAV) gene
therapy approach to express a SARM1 dominant-negative
transgene (Geisler et al., 2019b). We explore the mechanisms
linking TNF-α signaling to SARM1 in neuronal culture, demon-
strating that in a TNF-α–dependent neuronal necroptosis model,
SARM1 induces axon degeneration. Our findings demonstrate
that in contrast to canonical necroptotic cell death in which
MLKL (mixed lineage kinase domain-like pseudokinase) is the
final executioner, there exists a specialized “axonal necroptosis”
process in which MLKL works through the SARM1 axon de-
generation pathway to drive axon demise. Activated MLKL in-
duces loss of the axon survival factors NMNAT2 and SCG10/
STMN2, known inhibitors of SARM1 activation that are also lost
following axotomy, chemotherapy-induced neurotoxicity, and
mitochondrial dysfunction (Geisler et al., 2019a; Loreto et al.,
2020; Summers et al., 2020; Gilley et al., 2015). Hence, dispar-
ate upstream pro-degenerative signals converge on these axon
survival factors to activate SARM1. These studies identify mo-
lecular mechanisms linking neuroinflammation, necroptosis,
and SARM1 activation, and suggest that local inflammatory
signaling in the axon may drive SARM1-dependent axon loss.
This unification of three major drivers of neurodegeneration
may have broad implications for treatment of neurological
diseases.
Results
TNF-α induces SARM1-dependent axon loss and RGC death in a
neuroinflammatory model of glaucoma
Glaucoma is a neurodegenerative disease in which increased
IOP leads to neuroinflammation, triggering loss of optic
nerve axons and subsequent death of RGCs (Tezel and Wax,
2004; Bosco et al., 2011; Williams et al., 2017b, 2017c). SARM1
is the central executioner of axon degeneration in other
pathological conditions (Henninger et al., 2016; Geisler et al.,
2016), and we therefore investigated whether SARM1 pro-
motes the loss of RGC axons in response to TNF-α injection
into the vitreous cavity (Fig. 1 A), an established neuro-
inflammatory model of glaucoma.
We injected TNF-α or PBS into the vitreous cavity of 5-wk-
old WT and SARM1 knockout (KO) mice. We assessed axon
number in the optic nerve via EM and RGC number via Brn3a
staining of cell bodies in retinal whole mounts at 2 wk and 2 mo
after treatment. In this model, axon loss occurs by 2 wk, while
RGC loss is complete by 2 mo (Kitaoka et al., 2006, 2009, 2013;
Nakazawa et al., 2006; Roh et al., 2012). In agreement with prior
findings, optic nerves from TNF-α–treated WT eyes demon-
strated an ∼37% reduction in axon number, a degree of degen-
eration that would likely lead to abnormalities in visual field
testing in human patients (Kerrigan-Baumrind et al., 2000). In
WT axons, there is also a concomitant ∼26% increase in axon
size after 2 wk (Fig. 1, C and D). Analysis of the distribution of
axon sizes at 2 wk does not indicate the loss of a distinct cohort
of axons, as the distribution of axon sizes is similar between PBS
and TNF-α–treated WT axons (Fig. 2 E). In contrast, TNF-α
treatment in SARM1 KO mice did not lead to significant differ-
ences in optic nerve axon number or axon size. There is no
significant further loss of axons 2 mo following TNF-α injection
inWTmice; however, there is a continued increase in axon size,
driven largely by a population of large axons (>1.6 µm) that are
not apparent in PBS-treated or -untreated optic nerve (Fig. 1,
B–E). In contrast, SARM1 KO mice remain resistant to the ef-
fects of intravitreal TNF-α injection, showing no significant loss
of total axon number or increase in axon size at 2 mo following
TNF-α treatment (Fig. 1, B–E). Hence, there is not merely a delay
in axon degeneration in SARM1 KO mice; instead, SARM1 is
required for axon loss in this TNF-α–triggered glaucoma model.
Having assessed axon number, we next quantified RGC sur-
vival following intravitreal TNF-α injection. We stained retinas
with Brn3a to identify RGCs. While no RGC loss was observed at
2 wk (Kitaoka et al., 2006, 2009), there was significant loss of
RGCs inWT retinas 2 mo after TNF-α treatment (Fig. 1, F and G).
SARM1 KO mice were fully resistant to TNF-α–induced RGC
death, showing no significant decrease in RGC cell number at
2 mo (Fig. 1, F and G). Hence, loss of SARM1 protects both RGC
axons and cell bodies in this model of TNF-α–triggered glau-
coma. The temporal pattern of axon and cell body loss is con-
sistent with the idea that RGC death is a consequence of axon
degeneration.
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SARM1 is required for TNF-α–dependent oligodendrocyte
death but not microglial activation
Having demonstrated that loss of SARM1 protects RGC axons
and cell bodies from TNF-α–induced degeneration, we next
assessed whether SARM1 influenced other TNF-α–dependent
events. Intravitreal TNF-α injection activates microglia that
then amplify the inflammatory response (Nakazawa et al., 2006;
Roh et al., 2012; Son et al., 2010). To quantify microglial activa-
tion, we measured the size of microglial soma, as soma size in-
creases upon microglial activation while processes become less
complex (Davis et al., 2017). Intravitreal injection can tempo-
rarily activate microglia (Seitz and Tamm, 2014), so we first
performed control intravitreal PBS injections. In WT mice,
microglial soma size increased within 1 d and returned to a
normal soma size with more complex processes by 3 d. In age-
matched SARM1 KOmice, microglial soma size was also normal
3 d following intravitreal PBS injection (Fig. 2, A and B). In
contrast, intravitreal TNF-α injection led to microglial activa-
tion in both WT and SARM1 KO retina that persisted for at least
1 wk (Fig. 2, A and B). Therefore, intravitreal TNF-α stimulates
a sustained neuroinflammatory response in the retina that is
not SARM1-dependent. Hence, SARM1 is likely acting down-
stream of this neuroinflammatory response to promote axon
loss and RGC death.
Figure 1. TNF-α induces SARM1-dependent axon loss and RGC death in a neuroinflammatory model of glaucoma. (A) Schematic diagram of TNF-α
intravitreal (I.V.) injection. Axons and cell bodies are quantified at 2 wk (2w) or 2 mo (2m) following TNF-α or PBS injection. (B) EM of WT and SARM1 KO optic
nerves at 2 mo after PBS or TNF-α injection. Scale bar, 2 µm. (C and D) Quantification of axon number (C) and axon size (D) in the optic nerve of WT or SARM1
KOmice at 2 wk (2w) or 2 mo (2m) after intravitreal injection of PBS or TNF-α. Data represent the mean ± SEM; n = 4 or 5 for each condition; (C) axon number:
one-way ANOVA with post hoc Tukey test, F(7,30) = 21.1, P < 0.0001; (D) axon size: One-way ANOVA with post hoc Tukey test, F(7,34) = 15.27, P < 0.0001; *,
P < 0.05; **, P < 0.01; and ***, P < 0.001. (E) Histograms of the range of axon diameter at 2 wk (2w, left) and 2 mo (2m, right). Data are the same as used in C
and D. (F) Representative Brn3a immunostaining of WT and SARM1 KO retinas at 2 mo after TNF-α injection. Scale bar, 50 µm. (G) Quantification of the
number of Brn3a-positive RGCs in WT or SARM1 KO retina at 2 wk (2w) or 2 mo (2m) after PBS or TNF-α intravitreal injection. Data represent the mean ± SEM;
n = 4–7 for each condition; One-way ANOVA with post hoc Tukey test, F(7,36) = 13.2, P < 0.0001; *, P < 0.05; **, P < 0.01; and ***, P < 0.001.
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Figure 2. SARM1 mediates RGC and oligodendrocyte death in a neuroinflammatory model of glaucoma. (A) Representative Iba1 immunostaining of WT
and SARM1 KO retinas at 3 or 7 d after TNF-α or PBS intravitreal injection. Scale bar, 50 µm. (B) Quantification of microglial soma size at various times after
intravitreal injection of PBS or TNF-α of WT or SARM1 KO animals (No inj.: intact eye without injection). Data represent the mean ± SEM; n = 4–6 for each
condition; one-way ANOVAwith post hoc Tukey test, F(11,56) = 44.8, P < 0.0001; *, P < 0.05; **, P < 0.01; and ***, P < 0.001. (C) Representative CC1 and DAPI
immunostaining of WT and SARM1 KO optic nerves (cross-section) 7 d after TNF-α or PBS injection. Scale bar, 50 µm. (D) Quantification of mature oligo-
dendrocytes in WT and SARM1 KO optic nerves at 7 d after PBS or TNF-α treatment. Data are displayed as a percentage of oligodendrocytes present in WT
eyes injected with PBS. Data are represented as mean ± SEM; n = 4; One-way ANOVA with post hoc Tukey test, F(3,12) = 41.78, P < 0.0001; *, P < 0.05; **, P <
0.01; and ***, P < 0.001. (E) Quantification of G-ratio. The EM images used in Fig. 1, C and D, were analyzed. Data represent the mean ± SEM; n = 4–5 for each
condition; one-way ANOVA with post hoc Tukey test, F(7,30) = 0.7174, P = 0.6580; NS, not significant; *, P < 0.05; **, P < 0.01; and ***, P < 0.001. (F) Top:
Schematic diagram of AAV vector expressing human SARM1.DN (hSARM1.DN) under control of neuron-specific hSyn. Bottom: Representative retinal cross-
section. SARM1.DN protein (green) is present in the RGC layer (triangle) and RGC axons that colabel with TUJ1 (red). Inner nuclear layer (circle), outer nuclear
layer (square), cell bodies (DAPI, blue). Scale bar, 0.2 mm. (G) Top: Virus expressingWT SARM1 (AAV.SARM1.WT) or AAV.SARM1.DN is delivered via intravitreal
injection into WT mice. 4 wk later, TNF-α is injected intravitreally, and oligodendrocytes are quantified 7 d later. Bottom: Representative CC1 and DAPI
immunostaining of SARM1.WT or SARM1.DN-expressing optic nerve 7 d after TNF-α injection. Scale bar, 50 µm. (H) Quantification from G of the number of
mature oligodendrocytes following TNF-α injection (displayed as a percentage relative to the number observed in WT nerve following PBS intravitreal in-
jection). Data are represented as mean ± SEM, n = 4; two-tailed unpaired t test, SARM1.WT versus SARM1.DN, P = 0.0007; *, P < 0.05; **, P < 0.01; and ***, P <
0.001. (I) Immunoblot for pMLKL from optic nerve extracts derived fromWT or SARM1 KO animals 3 d after intravitreal injection of TNF-α or PBS or uninjected
control (No_inj). TUJ1 was used as a loading control. (J) Quantification of pMLKL expression from immunoblots. TUJ1 signal was used for normalization. Data
represent the mean ± SEM, n = 4; two-tailed unpaired t test, (WT) PBS_3d versus TNF_3d, P = 0.03; (SARM1KO) PBS_3d versus TNF_3d, P = 0.02; *, P < 0.05;
**, P < 0.01; and ***, P < 0.001. (K) Immunoblot for MLKL, RIPK3, and phosphorylated RIPK3 (pRIPK3) from optic nerve extracts derived fromWT or SARM1 KO
animals 3 d after intravitreal injection of TNF-α or PBS. TUJ1 was used as a loading control. (L)Quantification of the intensity of MLKL (n = 4), RIPK3 (n = 3), and
pRIP3 (n = 4) from immunoblots. TUJ1 signal was used for normalization. Data represent the mean ± SEM; two-tailed unpaired t test; (MLKL, WT) PBS_3d
versus TNF_3d, P = 0.014; (MLKL, SARM1 KO) PBS_3d versus TNF_3d, P = 0.005; (RIPK3, WT) PBS_3d versus TNF_3d, P = 0.028; (RIPK3, SARM1 KO) PBS_3d
versus TNF_3d, P = 0.018; (pRIPK3, WT) PBS_3d versus TNF_3d, P = 1.9E-06; (pRIPK3, SARM1 KO) PBS_3d versus TNF_3d, P = 0.03; *, P < 0.05; **, P < 0.01;
and ***, P < 0.001.
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While RGC death is central to the pathogenesis of glaucoma,
oligodendrocytes in the optic nerve are also lost in models of
glaucoma (Nakazawa et al., 2006; Son et al., 2010). Oligoden-
drocytes both insulate and provide metabolic support to RGC
axons in the optic nerve, and so we investigated whether oli-
godendrocytes are also preserved in the absence of SARM1 in
this glaucoma model. We stained for CC1, a marker of non-
proliferative mature oligodendrocytes (Payne et al., 2013), in
the optic nerves of TNF-α–treated WT and SARM1 KO mice.
In WT mice, TNF-α treatment decreased the number of CC1-
positive oligodendrocytes by ∼30% after 1 wk. Despite this
loss in oligodendrocyte number, there is no change in the
G-ratio of surviving axons (Fig. 2 E). Hence, oligodendrocyte
loss likely occurs concomitantly with axon loss, rather than
inducing aberrant myelination of surviving axons. In SARM1
KO animals, TNF-α treatment induced no significant loss of
oligodendrocytes in the optic nerve (Fig. 2, C and D). Hence,
SARM1 is required for oligodendrocyte death in response to
neuroinflammatory signaling.
The preservation of oligodendrocytes in TNF-α–treated
SARM1 KO mice could reflect a cell-autonomous action of
SARM1 in oligodendrocytes to drive cell death, or alternatively a
noncell autonomous role for axons in maintaining oligoden-
drocytes. To distinguish between these possibilities, we took
advantage of a dominant-negative SARM1 (SARM1.DN) that
potently blocks SARM1 function in vivo following viral delivery
(Geisler et al., 2019b). SARM1-DN fused to EGFP or WT SARM1
fused to EGFP were cloned into an AAV vector and expressed
under control of the neuron-specific human synapsin (hSyn)
promoter. A combination of the 7m8 capsid (Dalkara et al., 2013;
Büning and Srivastava, 2019) and hSyn promoter enabled robust
retinal expression that is limited to neurons (Fig. 2 F). 4 wk after
intravitreal injection of AAV2-hSyn-SARM1-DN-EGFP (AAV-
SARM1.DN) or control virus (AAV-SARM1.WT), we observed
robust EGFP labeling of RGCs and axons (Fig. 2 F; and Fig. S1, A
and B). In contrast, we do not observe expression in oligoden-
drocytes in the optic nerve (Fig. S1, C and D), allowing us to test
whether neuron-specific inhibition of SARM1 is sufficient to
block TNF-α induced oligodendrocyte death. Expression of WT
SARM1 (AAV-SARM1.WT) showed the expected loss of oligo-
dendrocytes 1 wk after intravitreal injection of TNF-α. In con-
trast, oligodendrocyte loss was significantly attenuated by
expression of the SARM1-DN in RGCs (Fig. 2, G and H). These
findings indicate that loss of oligodendrocytes is secondary to
SARM1-dependent function in RGCs, and suggests that mainte-
nance of healthy axons is required for oligodendrocyte survival
in response to neuroinflammatory signals.
Taken together, this series of experiments demonstrates that
SARM1 does not block the ability of TNF-α to induce neuro-
inflammatory stimulation of microglia, but is required for sub-
sequent oligodendrocyte death, axon loss, and RGC cell death.
Hence, SARM1 is an essential downstream mediator of neuro-
inflammatory damage in this model of glaucoma, and so is a
candidate therapeutic target for preventing neurodegeneration
in glaucoma.
Having explored the cellular consequences of intravitreal
TNF-α injection, we next investigated activation of pro-degenerative
molecular pathways. TNF-α can trigger apoptosis or nec-
roptosis in different contexts, including in promoting RGC
death in models of glaucoma (Fuchs and Steller, 2015; Weinlich
et al., 2017; Do et al., 2017; Almasieh et al., 2012). Hence, we
used immunoblotting to assess molecular markers of apoptosis
and necroptosis in the optic nerve following intravitreal TNF-α
injection. We did not detect cleaved caspase 3 via immuno-
blotting of optic nerve from TNF-α–injected eyes of either WT
or SARM1 KO mice (Fig. S2 A), consistent with our previous
demonstration that SARM1 does not participate in apoptosis
(Gerdts et al., 2013). We next investigated whether intravitreal
TNF-α activates necroptosis, an inflammatory form of pro-
grammed cell death (Kearney andMartin, 2017; Silke et al., 2015;
Heckmann et al., 2019). To assess activation of necroptotic sig-
naling, we assayed levels and phosphorylation of RIPK3 and
MLKL, two essential proteins for necroptosis (Ofengeim et al.,
2015; Caccamo et al., 2017; Ito et al., 2016; Vitner et al., 2014). At
3 d following intravitreal injection of TNF-α or PBS into WT and
SARM1 KO mice, we harvested optic nerves and performed
immunoblot analysis. In response to TNF-α injection, there was
a significant increase in the levels of phosphorylatedMLKL, total
MLKL, phosphorylated RIPK3, and total RIPK3 in optic nerves of
both WT and SARM1 KO mice (Fig. 2, I–L). Similar induction of
necroptotic signaling proteins is detected in other neurodegen-
erative diseases (Ofengeim et al., 2015; Caccamo et al., 2017;
Vitner et al., 2014; Ito et al., 2016; Zhang et al., 2017). Hence,
TNF-α activates necroptotic signaling in the optic nerve in a
SARM1-independent manner, suggesting that SARM1 may
function downstream of necroptosis to promote axon de-
generation and cell death.
A TNF-α–dependent neuronal necroptosis model triggers
SARM1-dependent axon degeneration in sensory neurons
To explore the relationships among TNF-α, necroptosis, and
SARM1, we turned to cultured dorsal root ganglion (DRG) neu-
rons, a pure neuronal population amenable to a mechanistic
analysis of axon degeneration (Fig. 3 A). We first developed a
TNF-α–dependent in vitro model of necroptosis in DRG neurons.
As there is cross-talk between apoptosis and necroptosis
(Heckmann et al., 2019), in cultured cells TNF-α can be biased to
stimulate necroptosis by simultaneously inhibiting apoptosis
with Z-VAD (carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-
fluoromethylketone) and blocking survival signaling with a
SMAC (second mitochondria-derived activator of caspases) mi-
metic (Gong et al., 2017; Wang et al., 2012). Using this cocktail,
we found that TNF-α treatment of DRG neurons induces the
phosphorylation of MLKL. This increase in phosphorylated
MLKL is blocked by necrostatin-1s, an inhibitor of RIPK1, a key
component of the necrosome required for MLKL phosphoryla-
tion during necroptosis (Fig. 3 B). Next, we assessed whether
TNF-α triggers axon degeneration in cultured DRG neurons.
Axons were imaged over time using an Operetta high-content
imaging system. Axon morphology was assessed via bright-field
imaging, and axonal energetics were examined using tetrame-
thylrhodamine methylester (TMRM), a fluorescent reporter of
mitochondrial potential. TNF-α induced axonal swelling by 48 h
and progressed to frank degeneration by 72 h, at which point
Ko et al. Journal of Cell Biology 5 of 17
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there was a dramatic loss in TMRM signal (Fig. 3 C). This
TNF-α–induced axon degeneration is driven by necroptosis,
as it is prevented in the presence of necrostatin-1s. Impor-
tantly, both the TNF-α–induced axonal degeneration and loss
of mitochondrial potential are fully blocked in SARM1 KO neu-
rons (Fig. 3, C–E). Hence, TNF-α and necroptosis require SARM1
to induce axon degeneration. While this cytokine-induced axon
degeneration is slower than axotomy-induced axon degenera-
tion, the common requirement for SARM1 demonstrates that
neuroinflammatory and necroptotic signaling in the axon share
molecular mechanisms with Wallerian degeneration.
Direct activation of necroptosis triggers SARM1-dependent
axon degeneration
While TNF-α can activate a model of necroptosis in DRG neu-
rons, in other cell types it can activate multiple death pathways
(Weinlich et al., 2017; Kearney and Martin, 2017; Heckmann
et al., 2019), making it more difficult to dissect the mechanis-
tic relationship between necroptosis and SARM1-dependent
degeneration. To test directly the hypothesis that SARM1 func-
tions downstream of necroptosis, we used an engineered variant
of MLKL that allows for temporal and spatial induction of nec-
roptosis (Gong et al., 2017; Orozco et al., 2014; Fegan et al., 2010;
Zhang et al., 2016). The N-terminal domain of MLKL (MLKL.ND)
was fused to FkbpF36v (Fig. 4 A, labeled with yellow), a protein
whose dimerization is induced in the presence of the rapamycin
analogue B/B homodimerizer (BB; star). Forced dimerization of
MLKL.ND with BB in DRG neurons shows several features of
necroptosis within 24 h (Fig. 4 B), including loss of cytosolic GFP
consistent with membrane rupture, externalization of phos-
phatidylserine as shown by annexin V staining, and cell death as
marked by nuclear accumulation of ethidium homodimer
(EthD), which does not enter live cells (Fig. 4 B). Interestingly, a
few neurons with annexin V membrane staining (arrowhead,
BB_24hr panel) show intact GFP fluorescence in cytosol and no
EthD fluorescence, suggesting that they are still alive. These
findings are consistent with the loss of membrane asymmetry
induced by ATP depletion or dysfunction of ATP-dependent
enzymes preceding membrane rupture during necroptosis
(Gong et al., 2017; Hankins et al., 2015). Taken together, these
findings show dimerized MLKL.ND causes necroptosis in DRG
neurons.
We next tested whether necroptosis induced by dimerization
of MLKL.ND triggers axon degeneration and assessed the re-
quirements for signaling proteins. We find that dimerization of
MLKL.ND causes axon degeneration and loss of TMRM staining
of WT axons within 24 h. Direct dimerization of MLKL.ND
should bypass the requirement for upstream RIPK activity, and
as predicted the RIPK1 inhibitor necrostatin-1s did not prevent
axon degeneration following dimerization of MLKL.ND (Fig. S3,
A and B). Dimerized MLKL.ND can interact with endogenous
MLKL to mediate downstream necroptotic signaling (Tanzer
et al., 2016). We knocked down MLKL with an shRNA target-
ing the C terminus of MLKL, so that it would not impact the
levels of the dimerizable MLKL.ND construct, and validated the
efficacy of the shRNA in both DRG neurons and in N2A cells that
express high levels of MLKL (Fig. S4). Upon knockdown of en-
dogenous MLKL, the dimerization of MLKL.ND does not trigger
axon degeneration (Fig. S5 A). In addition, the dimerization of
MLKL.ND increases the level of phosphorylated full-length
MLKL, and this is not blocked by necrostatin (Fig. S5, B and C).
Figure 3. TNF-α induces neuronal necroptosis and SARM1-dependent
axon degeneration in sensory neurons. (A) Schematic of embryonic day
13.5 DRG culture system. (B) Left: DRG neurons are treated with the indicated
compounds and axon-only extracts are immunoblotted for pMLKL. TNF-α
(100 ng/ml) is applied together with SMAC mimetic (LCL161, 10 µM) and pan
caspase inhibitor Z.VAD (100 µM). Necrostatin-1s (Nec), 20 µM. Right:
Quantification of pMLKL protein levels normalized to TUJ1 levels. Data are
represented as mean ± SEM, n = 3; one-way ANOVAwith post hoc Tukey test,
F(3,8) = 13.04, P = 0.0019; *, P < 0.05; **, P < 0.01; and ***, P < 0.001.
(C) Representative bright-field and TMRM images of cultured DRG axons
from WT or SARM1 KO neurons treated with TNF-α (together with 10 µM
LCL161, 100 µM Z.VAD) and necrostatin as indicated. Scale bar = 50 µm.
(D) DRG neurons from WT or SARM1 KO mice were treated with TNF-α
(together with 10 µM LCL161 and 100 µM Z.VAD) and necrostatin where
indicated. Axon degeneration was quantified from bright-field images at the
indicated time points after TNF-α application. Axons with a DI >0.3 are de-
fined as degenerated (dashed line). Data represent the mean ± SEM, n = 5;
two-way ANOVA with post hoc Bonferroni’s multiple comparison test; time,
F(2.217, 35.48) = 256, P < 0.0001; interaction, F(16,48) = 13.41, P < 0.0001; *,
P < 0.05; **, P < 0.01; and ***, P < 0.001. (E) Quantification of TMRM in-
tensity in axons after 72 h of TNF-α treatment (as described in D). TMRM (50
nM) was applied 30 min before image acquisition. Data represent the mean ±
SEM, n = 3; one-way ANOVA with post hoc Tukey test, F(3,8) = 71.72, P <
0.0001; *, P < 0.05; **, P < 0.01; and ***, P < 0.001.
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Hence, in this system, dimerized MLKL.ND recruits endogenous
MLKL to mediate downstream axon degeneration.
With this system in hand, we asked if axon degeneration
induced by MLKL.ND dimerization requires SARM1. In contrast
to WT neurons, axons from SARM1 KO neurons were fully
protected from both axon degeneration and loss of mitochon-
drial potential for at least 48 h after MLKL.ND dimerization
(Fig. 4, C and D). We also assessed calcium influx, a common
feature of necroptosis and Wallerian degeneration. While the
mechanism of calcium influx during necroptosis is not fully
understood, there is a consensus that calcium influx is the
consequence of membrane permeabilization induced by MLKL
(Wang et al., 2014; Su et al., 2014; Cai et al., 2014; Xia et al., 2016).
We used live-cell imaging to simultaneously monitor intracel-
lular calcium using GCaMP6 (Chen et al., 2013) and axonal in-
tegrity with mRuby3, a photostable fluorescent cytosolic protein
(Bajar et al., 2016). In WT axons, dimerization of MLKL.ND
triggered calcium influx and axon degeneration that was com-
pletely prevented in axons from SARM1 KO neurons (Fig. 4, E
and F; and Video 1). This is a surprising finding, since in other
systems MLKL induces calcium influx via direct membrane
permeabilization. In contrast, in axonal necroptosis, SARM1
becomes activated and triggers calcium influx and axon degen-
eration. Interestingly, this relationship is selective for the axon,
as in the cell body the activation of necroptosis via dimerization
of MLKL.ND triggered calcium influx followed by membrane
rupture in both WT and SARM1 KO neurons (Video 1). Indeed,
there is no significant difference in the extent of cell death in-
duced by necroptosis inWT versus SARM1 KO neurons (Fig. S6).
Taken together, these findings suggest the exciting hypothesis
that canonical necroptotic signaling drives cell death in sensory
neurons, but that a specialized form of axonal necroptosis uses a
distinct SARM1-dependent mechanism to trigger calcium influx
and axon degeneration.
As a first test of this hypothesis, we investigated whether
other components of the SARM1 Wallerian degeneration path-
way function downstream of necroptosis for axon degeneration.
In classical Wallerian degeneration, overexpression of the axon
Figure 4. Direct activation of necroptosis triggers SARM1 dependent axon degeneration. (A) Top: Schematic of MLKL and dimerizable MLKL.ND
construct (MLKL.ND = MLKL N-terminal domain) used in this study. MLKL.ND is fused to FkbpF36V. Bottom: Neurons are infected with lentivirus expressing
MLKL.ND, and dimerization is induced with BB (100 nM) to promote necroptosis. (B) Representative images of cell bodies of cultured DRG neurons expressing
MLKL.ND at baseline (left) and 24 h after BB (100 nM) application (right). After 24 h, most cells have died from necroptosis (lose both Hoechst staining and
soluble GFP fluorescence: gain both annexin V and EthD staining). In two cells (arrow), annexin V is detected before EthD staining or loss of both Hoechst and
cytosolic GFP, suggesting that annexin V staining is an early sign of impending cell death. Hoechst (blue), cytosolic GFP (green), annexin V (red), EthD (yellow);
scale bar, 30 µm. (C) Representative bright-field and TMRM images of axons fromWT and SARM1 KO DRG neurons expressing MLKL.ND at baseline (left) and
24 h after BB (100 nM) treatment (right). Scale bar, 50 µm. (D) Quantification of axon degeneration (left, n = 5) and TMRM intensity (right, n = 3) at the
indicated time points after BB (100 nM) addition to WT or SARM1 KO neurons. Axons with a DI >0.3 are defined as degenerated (dashed line). Data represent
the mean ± SEM. For axon degeneration, two-way ANOVA with post hoc Bonferroni’s multiple comparison test; time, F(2,16) = 106.5, P < 0.0001; interaction,
F(8,16) = 4.635, P = 0.0044. For TMRM, two-tailed unpaired t test, P < 0.0001; *, P < 0.05; **, P < 0.01; and ***, P < 0.001. (E) Representative fluorescent
images of WT or SARM1 KO axons infected with lentivirus encoding the calcium reporter GCaMP6, the axon integrity reporter mRuby3, and MLKL.ND at
baseline and 21 h after BB application. Scale bar, 30 µm. (F) Depiction of Ca2+ dynamics with GCaMP6 fluorescent intensity (green, left y axis), and axon
integrity with mRuby3 fluorescent intensity (red, right y axis) from a representative single axon of each genotype from E (arrowhead).
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survival factor cytoNMNAT1 and inhibition of the neuronal stress
kinases DLK (dual leucine zipper kinase) and LZK (leucine zipper-
bearing kinase) potently inhibit axotomy-induced axon
degeneration (Summers et al., 2018). UponMLKL.ND dimerization-
induced necroptosis, cytoNMNAT1 overexpression and treat-
ment with the DLK/LZK inhibitor GNE-3511 both potently block
axon degeneration (Fig. S7). These findings support the hy-
pothesis that axonal necroptosis can stimulate the canonical
Wallerian degeneration program to drive axon loss. DLK inhi-
bition can block apoptotic neuronal cell death (Ghosh et al.,
2011), but as with SARM1 KO, does not block necroptotic cell
death induced by MLKL.ND dimerization (Fig. S7). These
findings highlight that necroptosis-induced cell death and
necroptosis-induced axon degeneration are mechanistically
distinct.
Axonal necroptosis triggers local axon degeneration
While necroptosis induces degeneration via distinct mecha-
nisms in the cell body and the axon, MLKL.ND is dimerized
throughout the cell, and so it is not possible to determine
whether there is a local axonal necroptotic program or whether
the axonal effects are secondary to cell body death. To distin-
guish between these possibilities, we used microfluidic devices
to spatially isolate axons from cell bodies, allowing us to test
whether dimerization of MLKL.ND exclusively in axons is suf-
ficient to trigger axon degeneration (Fig. 5 A). Dissociated DRG
neurons expressing MLKL.ND were seeded in the somal com-
partment and extended their axons into the axonal compart-
ment of the microfluidic devices.
To test the hypothesis that necroptosis can occur axon au-
tonomously, we performed three independent experiments.
First, addition of the BB dimerizing agent to the axonal side of
microfluidic devices was sufficient to induce loss of axonal
TMRM staining and local axon degeneration without cell body
death.Moreover, this axon degeneration and TMRM loss require
SARM1 (Fig. 5, B and C). Hence, local axonal induction of nec-
roptosis in the absence of cell death induces SARM1-dependent
axon degeneration. While local axon degeneration is robust in
this paradigm, the extent of axon degeneration in microfluidic
devices is less dramatic than in normal culture dishes, sug-
gesting that concurrent induction of necroptosis in the soma
may contribute to this degenerative event (compare with Fig. 4
C). Second, we observed local calcium influx in axons following
axonal-induction of necroptosis. Following axonal application of
the BB dimerizer, live-cell imaging revealed a large calcium in-
flux in axons, but not in soma, ofWT but not SARM1 KO neurons
(Fig. 5 D and Video 2 shows absence of somal calcium influx over
time). Taken together, these two experiments show that axonal
activation of necroptosis triggers local, SARM1-dependent loss of
mitochondrial potential, calcium influx, and axon degeneration.
These studies show that local necroptosis can stimulate the
SARM1 degeneration program, but they rely on an engineered
system to activate axonal necroptosis. We wondered whether
endogenous mechanisms can activate axonal necroptosis in the
absence of cell body necroptosis. To test this hypothesis, we
asked whether axon-only application of TNF-α could induce
local necroptosis as assayed by phosphorylation of MLKL. For
immunoblot analysis, microfluidic devices do not provide
enough axonalmaterial. Hence, wemade spot cultures of SARM1
KO DRG neurons on standard culture dishes, allowed axons to
extend, and then removed all cell bodies. Since SARM1 blocks
axotomy-induced axon degeneration, these axons remain intact
and metabolically healthy for at least 5 d (Geisler et al., 2019b),
thus providing adequate time to examine necroptotic signaling.
First, we showed that severed axons treated with DMSO for 40 h
do not show increases in phosphorylated MLKL (pMLKL),
demonstrating that axotomy alone does not increase pMLKL
(Fig. 5 E). We then applied TNF-α to these isolated severed ax-
ons, collected samples 40 h after TNF-α application, and found
that TNF-α triggers an increase in the levels of phosphorylated
MLKL that is blocked by the application of necrostatin. Hence,
local TNF-α can trigger the necroptotic cascade in axons (Fig. 5
E). This could have important implications for diseases such as
multiple sclerosis, where local neuroinflammatory signaling
could directly impact axonal health.
Necroptosis depletes axon survival factors
We next investigated the mechanism by which dimerized
MLKL.ND activates SARM1 to promote axon degeneration. For
axonal maintenance, axon survival factors such as NMNAT2 and
SCG10/STMN2 are continuously supplied to the axon to inhibit
SARM1 (Gilley et al., 2015; Walker et al., 2017; Shin et al., 2012).
Therefore, we testedwhether necroptosis decreases NMNAT2 and
SCG10 levels in axons. After activation of necroptosis via dimer-
ization of MLKL.ND, axonal NMNAT2 levels significantly de-
creased over the ensuing 16 h (Fig. 6, A and B). This loss of
NMNAT2 only occurs in axons, as there is no change in the levels
of somal NMNAT2 (Fig. 6, C and D). Moreover, the levels of axonal
SCG10 also decreased after dimerization of MLKL.ND, showing
that coregulation of these axon maintenance factors occurs
downstream of necroptosis (Fig. 6, C and D). Finally, having
demonstrated that endogenous MLKL is required for axon de-
generation induced by MLKL.ND dimerization (Fig. S5), we also
find that endogenousMLKL is required for the rapid loss of axonal
NMNAT2 after dimerization of MLKL.ND (Fig. 6, E and F). Hence,
axonal necroptosis triggers the rapid loss of NMNAT2.
SARM1 NAD+ cleavage activity is required for
necroptosis-induced axon degeneration
SARM1 is an inducible NAD+ cleavage enzyme. DuringWallerian
degeneration, SARM1 cleaves NAD+, triggering a metabolic crisis
with loss of ATP and subsequent axon degeneration (Fig. 7 A;
Sasaki et al., 2020; Essuman et al., 2017; Gerdts et al., 2016).
However, SARM1 is also a TLR (Toll-like receptor)-adaptor
protein that may participate in traditional innate immune sig-
naling (Mukherjee et al., 2013) separate from its newly found
role as an enzyme. Hence, we tested whether this SARM1
NADase activity is required for necroptosis-triggered axon
degeneration. First, we assessed the requirement for catalyti-
cally active SARM1. The glutamic acid at position 642 is the
catalytic residue of the SARM1 NADase, and mutations at posi-
tion 642 render SARM1 incapable of mediating Wallerian de-
generation (Essuman et al., 2017). Here we dimerized MLKL.ND
in SARM1 KO neurons expressing GFP, WT SARM1, or the
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catalytically dead SARM1-E642A. MLKL.ND dimerization trig-
gers axon degeneration only in neurons expressingWT SARM1,
demonstrating that catalytically active SARM1 is required for
necroptosis-induced axon degeneration (Fig. 7, B and C). Next,
we tested whether axon degeneration could be blocked down-
stream of SARM1 by boosting synthesis of NAD+ or ATP. During
Wallerian degeneration, addition of the NAD+ precursor nico-
tinamide riboside (NR) while overexpressing NR kinase (NRK1)
increases NAD+ levels and delays axon degeneration (Sasaki
et al., 2016), while incubating neurons with methyl-pyruvate
boosts ATP levels (Yang et al., 2015; Cheong et al., 2011). In the
presence of NRK1 plus NR or methyl-pyruvate, axon degenera-
tion induced by MLKL.ND dimerization is blocked for at least 24
h. At 48 h, axons are beginning to show minor signs of degen-
eration (Fig. 7 E). These findings indicate that necroptosis in-
duces a SARM1-dependent metabolic crisis in the axon, and
suggest that the mechanisms downstream of SARM1 are likely
the samewhether SARM1 is activated by axotomy or necroptosis.
Discussion
Our understanding of the molecular mechanisms of neuro-
degeneration has expanded dramatically with the realization
that neuroinflammation contributes to most neurodegenerative
diseases (Hammond et al., 2019), that necroptosis is likely as
important as apoptosis in driving neuronal cell death (Weinlich
et al., 2017; Yuan et al., 2019), and that SARM1 is the central
executioner of an axonal self-destruction program activated in
diverse neurodegenerative conditions (Figley and DiAntonio,
2020). Here, we unite these disparate degenerative pathways,
identifying molecular and functional links among neuro-
inflammation, necroptosis, and SARM1-mediated axonal self-
destruction. These studies support a model in which local
neuroinflammatory signals can activate an axonal form of nec-
roptosis that in turns triggers SARM1 NADase activity and ax-
onal demise. These findings have important mechanistic and
therapeutic implications for a broad range of neurodegenerative
disorders.
SARM1 promotes RGC and oligodendrocyte death in a
neuroinflammatory model of glaucoma
While high IOP is the proximate cause of most cases of
glaucoma, it is now appreciated that glaucoma is a neuro-
degenerative disease with a major neuroinflammatory
component (Weinreb et al., 2014). Indeed, glaucoma can
occur despite normal IOPs, and many patients with high IOP
Figure 5. Axonal necroptosis triggers local axon degeneration. (A) Schematic diagram of microfluidic device. BB (100 nM) is applied to the axon compartment
to dimerize MLKL.ND locally. (B) Representative bright-field and TMRM images of soma (left) and axons (right) 24 h after BB is applied to the axon compartment.
Scale bar, 50 µm. (C) Quantification of axon degeneration (top) and TMRM intensity (bottom). Axons with a DI >0.3 are defined as degenerated (dashed line). Data
are represented as mean ± SEM, n = 3. For axon degeneration; one-way ANOVA with post hoc Tukey test, F(3, 8) = 29.47, P = 0.0001; for TMRM, one-way ANOVA
with post hoc Tukey test, F(3, 8) = 23.28, P = 0.0003; *, P < 0.05; **, P < 0.01; and ***, P < 0.001. (D) Representative fluorescent images of soma (left) and axons
(right) from WT or SARM1 KO DRG neurons cultured in microfluidic devices. BB is only applied to the axon compartment. Scale bar, 30 µm. (E) Left: Schematic of
cultured DRGs in which cell bodies have been removed before TNF-α treatment in order to obtain axon-only lysate. Middle: SARM1 KO severed axons are treated
with DMSO or TNF-α (100 ng/ml) together with SMAC mimetic (LCL161, 10 µM) and Z.VAD (100 µM) with or without necrostatin-1s (Nec, 20 µM). Axonal extracts
are immunoblotted for phosphorylated MLKL. TUJ1 is used as a loading control. Right: Quantification of pMLKL normalized to TUJ1 level. Data represent the mean ±
SEM, n = 4; one-way ANOVA with post hoc Tukey test, F(2.014, 6.041) = 15.02, P = 0.0045; *, P < 0.05; **, P < 0.01; and ***, P < 0.001. AxD, axon degeneration.
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experience continued visual field loss even after restoration
of normal pressure (Beidoe and Mousa, 2012). Hence, there
is great interest in developing neuroprotective strategies
that could be combined with pressure-lowering medications
for the treatment and prevention of glaucoma. Here we
identify SARM1 as a therapeutic target for neuroprotection
in glaucoma.
Using a neuroinflammatory model of glaucoma induced by
intravitreal TNF-α injection, we find that SARM1 is required
for RGC axon loss and cell death as well as oligodendrocyte
loss in the optic nerve. In this system, microglia are activated
within days, oligodendrocyte death and RGC axon loss occurs
within 2 wk, and ultimately RGC neurons die by 2 mo. Our
data demonstrate that SARM1 is not required for microglia
activation. Therefore, we suggest that SARM1 functions down-
stream of neuroinflammatory signaling to promote axonal self-
destruction, which in turn promotes oligodendrocyte and RGC
death. A variety of results supports the model that axon loss is
the driver of oligodendrocyte and RGC death. First, using viral
delivery of a neuronally expressed SARM1 dominant-negative
transgene provides noncell autonomous protection to oligoden-
drocytes following TNF-α treatment. Since this oligodendrocyte
loss occurs well before RGC death but around the same time as
RGC axon loss, it is likely secondary to SARM1-mediated axonal
degeneration. Second, while SARM1 can promote neuronal cell
death, it does not promote apoptotic cell death (Gerdts et al.,
2013; Summers et al., 2014), the likely mechanism of RGC
death in glaucoma (Syc-Mazurek and Libby, 2019). Indeed, in-
hibiting apoptosis blocked RGC death in the DBA/2 chronic
glaucoma model, but failed to protect optic nerve axons (Libby
et al., 2005). In contrast, following optic nerve transection,
SARM1 KO blocks degeneration of the severed distal axons,
but does not protect against cell body death, which instead is
mediated by retrograde axonal signals that activate apoptosis
(Welsbie et al., 2013; Simon and Watkins, 2018; Syc-Mazurek
and Libby, 2019). The different requirements for SARM1 fol-
lowing optic nerve transection and TNF-α application are in-
structive. Transection directly disrupts axons, thereby triggering
retrograde apoptotic signals, while with TNF-α treatment,
SARM1-induced axon degeneration is the cause of the axon
loss that likely activates the apoptotic signals. Hence, by in-
hibiting SARM1, axons are protected and secondary apoptotic
signaling is prevented.
A role for SARM1 in glaucoma may explain the mechanism of
metabolic dysfunction in glaucomatous optic nerves. In DBA/2J,
ATP levels in optic nerve are dramatically reduced at 6 mo, well
before optic nerve loss (Baltan et al., 2010; Inman andHarun-Or-
Rashid, 2017; Libby et al., 2005; Howell et al., 2007). SARM1 is an
inducible NAD+ cleaving enzyme, and SARM1 activation induces
axonal NAD+ loss that is followed by ATP loss, likely due to the
central role of NAD+ in both oxidative phosphorylation and
glycolysis (Essuman et al., 2017; Gerdts et al., 2016). If neuro-
inflammation induces low-level SARM1 activation, this may
trigger metabolic vulnerability of glaucomatous optic axons and
explain the protective effects of NAD+ supplementation (Kitaoka
et al., 2009; Williams et al., 2017b) and overexpression of the
NAD biosynthetic enzymeNMNAT inmany (Howell et al., 2007;
Kitaoka et al., 2009; Williams et al., 2017a; Zhu et al., 2013), but
not all, glaucoma models (Beirowski et al., 2008).
TNF-α is up-regulated in the vitreous, retina, and optic
nerves of glaucoma patients (Yan et al., 2000; Sawada et al.,
2010; Tezel et al., 2001; Huang et al., 2010) as well as in re-
sponse to increased IOP in rodent models (Roh et al., 2012;
Nakazawa et al., 2006; Cueva Vargas et al., 2015). Pharmacological
Figure 6. Axonal necroptosis depletes axon survival factors. (A) Rep-
resentative immunoblot of axonal NMNAT2 from WT DRG neurons ex-
pressing MLKL.ND at the indicated times following dimerization of MLKL.ND
with BB. (B) Quantification of axonal NMNAT2 normalized to TUJ1 for the
conditions in A. Data represent the mean ± SEM, n = 3 to 4; One-way ANOVA
with post hoc Tukey test, F(4, 12) = 24.51, P < 0.0001; 0 h versus 4 h, P =
0.0013; 0 h versus 8 h, P = 0.0002; 0 h versus 12 h, P < 0.0001; 0 h versus 16
h, P < 0.0001; *, P < 0.05; **, P < 0.01; and ***, P < 0.001. (C) Immunoblot for
the axonal survival factors NMNAT2 and SCG10 from axons and soma of WT
DRG neurons expressing MLKL.ND at 0 and 8 h after BB treatment. TUJ1 is
used as a loading control. (D) Quantification of NMNAT2 and SCG10 levels
normalized to TUJ1 from axons or soma 8 h after BB application as described
in C. Values are displayed as percentage of 0 h baseline. Data represent the
mean ± SEM, n = 4; two-tailed unpaired t test, soma SCG10, P = 0.065; axon
SCG10, P = 0.0001; soma NMNAT2, P = 0.47; axon NMNAT2, P < 0.0001; NS,
not significant; *, P < 0.05; **, P < 0.01; and ***, P < 0.001. (E) Representative
immunoblot of NMNAT2 in axonal lysates from WT neurons expressing
MLKL.ND treated with an shRNA to MLKL or a control shRNA. TUJ1 is used as
a loading control. Axonal lysates are collected at baseline and 8 h after BB
addition. (F)Quantification of axonal NMNAT2 levels normalized to TUJ1 from
immunoblots as in E. Data represent the mean ± SEM, n = 3; one-way ANOVA
with post hoc Dunnett’s multiple comparison test, F(1.288, 2.575) = 29.26, P =
0.0177; *, P < 0.05; **, P < 0.01; and ***, P < 0.001.
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and genetic manipulation of TNF-α signaling demonstrates that
it promotes microglial activation, yet how that ultimately
triggers RGC axon loss and death remains unknown. Here we
show that TNF-α application rapidly induces the up-regulation
and phosphorylation of RIPK3 and MLKL in optic nerve, con-
sistent with induction of necroptosis. We also show that TNF-
α–dependent loss of oligodendrocytes, RGC axons, and RGC cell
bodies is SARM1-dependent. These data, in conjunction with
prior studies in glaucoma, are consistent with a model in which
increases in IOP trigger TNF-α release, which in turn activates
microglia, initiating a positive feedback loop that leads to fur-
ther release of damaging cytokines. These inflammatory factors
may then act on RGC axons to trigger an axonal form of nec-
roptosis that activates SARM1 NADase activity. Accordingly,
activated SARM1 would impair RGC axonal metabolism and
promote axon degeneration and loss of associated oligoden-
drocytes. Once the axon is disconnected from its target, ret-
rograde apoptotic signals would promote death of RGCs. If this
model were correct, then pharmacological or gene therapy
approaches to inhibit SARM1 would be neuroprotective in
glaucoma, maintaining axonal integrity and blocking down-
stream death of oligodendrocytes and RGCs. Moreover, such a
mechanism is unlikely to be limited to the eye, and may be
broadly relevant to neurodegenerative diseases associated
with neuroinflammation.
Axonal necroptosis triggers SARM1-dependent axon
degeneration
In classical Wallerian degeneration, the mechanism of SARM1-
dependent axon degeneration is well understood. In a healthy
axon, SARM1 is held inactive via inhibition by the axonal sur-
vival factors NMNAT2 and SCG10/STMN2. Both NMNAT2 and
SCG10 are labile with very short half-lives, and so they must be
constantly replenished in the axon via fast axonal transport.
Upon axotomy, no new NMNAT2 or SCG10 can be delivered to
the distal axon, and levels of these axon survival factors conse-
quently drop, allowing stimulation of SARM1 NADase activity
and triggering a metabolic crisis and axonal degeneration. A
similar mechanism is thought to occur in response to neurotoxic
chemotherapeutics such as vincristine, which disrupt axonal
transport without a frank transection, and so would be expected
to reduce NMNAT2 and SCG10 at the most distal portion of the
axon. This likely explains the distal dying-back pathology that is
a hallmark of peripheral neuropathy. Here, we greatly expand
the reach of this model for SARM1 activation, demonstrating
that neuroinflammatory and necroptotic signaling in the axon
reduces the levels of the axonal survival factors NMNAT2 and
SCG10 and triggers SARM1-dependent axonal degeneration. Since
neuroinflammation and necroptosis are major contributors to a
broad range of neurodegenerative diseases, and since axon
degeneration is an early and major contributor to neuropathology
Figure 7. SARM1 NADase activity is required for
necroptosis-induced axon degeneration. (A) Schematic
diagram of interventions that impact SARM1-mediated
axon degeneration. Glutamic acid 642 (E642) is the cata-
lytic residue of the SARM1 NADase. NRK1 + NR promote
NAD+ synthesis. Methyl pyruvate (Me_Pyruvate) promotes
ATP synthesis. (B) Representative bright-field and TMRM
images of axons of SARM1 KO DRG neurons expressing
MLKL.ND at 24 h after BB application. SARM1 KO neurons
expressing MLKL.ND are infected with lentivirus expressing
either GFP as a control (CTL), WT SARM1 (SARM1.WT), or
catalytically dead SARM1 (SARM1.E642A). Scale bar, 50 µm.
(C) Quantitative analysis of axon degeneration at the indi-
cated times after BB (100 nM) application from bright-field
images for the conditions described in B. Axons with a
DI >0.3 are defined as degenerated (dashed line). Data
represent the mean ± SEM, n = 4; two-way ANOVA with
post hoc Bonferroni’s multiple comparison test; time,
F(1.472, 13.25) = 102.7, P < 0.0001; interaction, F(9, 18) =
12.88, P < 0.0001; *, P < 0.05; **, P < 0.01; and ***, P <
0.001. (D) Representative bright-field and TMRM images of
axons of WT DRG neurons expressing MLKL.ND 24 h after
BB addition. Neurons are treated with 1 mM NR while in-
fected with lentivirus expressing NRK1, 5 mMMe_Pyruvate,
or no addition (CTL, control). Scale bar, 100 µm. (E) Quanti-
tative analysis of axon degeneration at the indicated times
after BB addition from bright-field images for the conditions
described in D. Axons with a DI >0.3 are defined as degen-
erated (dashed line). Data represent the mean ± SEM, n = 3;
two-way ANOVA with post hoc Bonferroni’s multiple com-
parison test; time, F(1.472, 13.25) = 102.7, P < 0.0001; inter-
action, F(9, 18) = 12.88, P < 0.0001; *, P < 0.05,; **, P < 0.01;
and ***, P < 0.001.
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in many of these disorders, we hypothesize that the molecular
links identified here among neuroinflammation, necroptosis,
and SARM1 activity are important mediators of axon loss in
these diseases.
Here, we provide evidence for a specialized form of nec-
roptosis that works in the axon through SARM1 to promote axon
degeneration. First, we show that TNF-α stimulates necrostatin-
and SARM1-dependent axon degeneration, and find that TNF-α
application exclusively to axons triggers necroptosis as assayed
by phosphorylation of MLKL. Hence, the machinery for nec-
roptosis is present in the axons. Second, we demonstrate that
direct activation of necroptosis via dimerization of MLKL.ND
works through endogenous MLKL to trigger mechanistically
distinct degenerative outcomes in the axon versus cell body. In
the cell body, dimerized MLKL.ND induces calcium influx and
cell death that is SARM1-independent, which is consistent with
the canonical role for MLKL as an inducer of membrane per-
meabilization, either directly via forming a pore or through
activation of TRPM7 channels (Cai et al., 2014; Xia et al., 2016). In
the axon, however, dimerized MLKL.ND requires SARM1 to
trigger calcium influx and axon degeneration, implying that
axonal MLKL is not sufficient to disrupt membranes. This is a
very surprising finding given the “pore forming” function of
MLKL in canonical necroptosis. Instead, we show that dimerized
MLKL.ND and endogenous MLKL promote the loss of the axon
survival factors NMNAT2 and SCG10. Once axonal necroptosis
lowers levels of these survival factors, the mechanism of axon
degeneration is similar to that observed for Wallerian degen-
eration. Whether triggered by axonal necroptosis or axotomy,
axon loss requires SARM1 NADase activity, is blocked by over-
expression of cytoplasmic NMNAT1 or inhibition of the DLK/
LZK stress kinases, and involves metabolic catastrophe that can
be rescued via supplementation with NAD+ and ATP precursors.
How might axonal necroptosis trigger loss of the axonal
survival factors NMNAT2 and SCG10? The finding that axonal
necroptosis coregulates both factors is a clue, as we have pre-
viously demonstrated that palmitoylated forms of NMNAT2 and
SCG10 colocalize to axonal vesicles, and are coregulated by DLK/
LZK working through a JNK neuronal stress pathway (Summers
et al., 2018). JNK activity promotes the turnover of both
NMNAT2 and SCG10. Interestingly, necroptosis can also stim-
ulate JNK activation (McNamara et al., 2013; Gautheron et al.,
2014), and hence this could be a mechanism by which nec-
roptosis stimulates SARM1-dependent axon degeneration.
There is controversy about whether or not necroptosis con-
tributes to traditional Wallerian degeneration. Yang et al. (2015)
reported that inhibiting necroptosis does not influence
axotomy-induced Wallerian degeneration, but a recent study
from Arrázola et al. (2019) claimed that axotomy activates nec-
roptosis and promotes Wallerian degeneration. Our results are
consistent with previous findings (Yang et al., 2015), as we do
not see activation of necroptosis in response to axotomy, and
neither genetic nor pharmacological inhibition of necroptosis
blocks axotomy-induced axon degeneration (Fig. S8). However,
the recent findings that necroptosis promotes axon degeneration
in both excitotoxicity and Parkinson’s models (Hernández et al.,
2018; Oñate et al., 2020) are consistent with the findings
reported here, although the role of the SARM1 pathway was not
explored in those studies.
Here, we identify a central role for SARM1 in promoting
axon, RGC, and oligodendrocyte loss in glaucoma. Major efforts
are underway to develop pharmacological and gene therapy
approaches to inhibit SARM1 (DiAntonio, 2019), and hence
SARM1 is a realistic therapeutic target for neuroprotection in
glaucoma. In addition, we identify a specialized form of axonal
necroptosis that links neuroinflammation to SARM1-dependent
axon degeneration. This unification of three major neurode-
generative mechanisms has broad implications for the patho-
genesis and treatment of a wide range of neurodegenerative
disorders. This finding may be of particular interest in diseases
such as multiple sclerosis, where neuroinflammation may di-
rectly impact the axon.
Materials and methods
Further information about resources and materials is listed in
Table S1.
Animals
All procedures were performed in accordance with guidelines
mandated in the National Institutes of Health Guide for the Care
and Use of Laboratory Animals and approved by theWashington
University School of Medicine in St. Louis Institutional Animal
Care and Use Committee. C57BL/6 mice were purchased from
Jackson Laboratory, and SARM1KO mice were a gift from M.
Colonna at Washington University in St. Louis (Szretter et al.,
2009). CD1 mice (gestation day 11.5) for sensory neuron cultures
was purchased from Charles River Laboratories.
Intravitreal injection
2 µl TNF-α (1 ng in 1 µl of PBS with 0.1% BSA) or PBS was in-
jected into the vitreous chamber of one eye of 5-wk-old mice
(WT or SARM1 KO) using a syringe pump (Harvard Apparatus
22 syringe pump; Harvard Apparatus). A 33-gauge beveled
needle (NanoFil) is used for 5-wk-old mice. Given that the vit-
reous volume is ∼10 µl (Remtulla and Hallett, 1985; Sharma
et al., 2005; Yu and Cringle, 2006), the concentration of
TNF-α is ∼0.2 mg/ml. Only one eye was injected with TNF-α or
PBS for experiments. The needle tip with 45° angle was slowly
inserted into the vitreous body through the sclera of the superior
hemisphere of the eye. The speed of the injection is 7.5 µl/min. If
eyes are damaged resulting in retinal detachment or bleeding,
and/or iris/lens injury, then those eyes were excluded for data
analysis because previous studies have shown that eye injury
releases neuronal survival factors (Fischer et al., 2001; Leon
et al., 2000).
AAV constructs and virus injection
AAV vector expressing EGFP (pAAV-hSyn-EGFP) was obtained
from Addgene (gift from B. Roth, School of Medicine at the
University of North Carolina at Chapel Hill, Chapel Hill, NC;
Addgene 50465). This vector was cut with BamHI and NcoI, and
then SARM1.WT or SARM1-K193R/H194A/H685A (SARM1.DN)
was inserted between the synapsin promoter and EGFP
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sequence using in-Fusion HD Cloning kit (Clontech; Geisler
et al., 2019b). In the retina, viral expression driven by the syn-
apsin promoter is weaker than that of the commonly used
nonneuronal promoter chicken-b-actin promoter with cyto-
megalovirus enhancer, so we used a capsid mutant, 7m8, to
overcome tissue penetration for gene delivery (Yin et al., 2011;
Dalkara et al., 2013). This virus is delivered with intravitreal
injection like TNF-α injection.
DRG neurons culture/experimental timeline
Mouse DRG neurons were dissected from embryonic days 13.5 or
14.5 from CD1 mouse embryos. DRG neurons were incubated
with 0.05% trypsin containing 0.02% EDTA at 37°C for 20 min
and then resuspended in neurobasal media (Gibco) containing
2% B27 (Invitrogen), 50 ng/ml nerve growth factor (Harlan
Laboratories), 1 µM 5-fluoro-2deoxyuridine (Sigma-Aldrich),
1 µM uridine (Sigma-Aldrich), and penicillin/streptomycin
(Thermo Fisher Scientific). The dissociated DRG neurons were
plated in 24-well or 96-well plates (Corning) coated with poly-
D-lysine (0.1 mg/ml; Sigma-Aldrich) and laminin (3 µg/ml;
Invitrogen) and then allowed to adhere in humidified tissue
culture incubator (5% CO2) for 15 min. Finally, DRG growth
medium was gently added (500 µl for 24-well, 100 µl for 96-
well). Lentivirus was transduced at 1 or 2 d in vitro (DIV). At
DIV7, assays for axon degeneration and/or cell death were per-
formed by applying BB (or TNF-α) or axotomy.
Lentivirus construction/production
The following murine MLKL-specific (target sequence: 59-GAG
ATCCAGTTCAACGATA-39) shRNA was engineered using two
primers (Integrated DNA Technologies) that were annealed,
phosphorylated, and ligated into AgeI and EcoRI restriction sites
of pLKO.1 vector: shMLKL (59-CCGGTGGAGATCCAGTTCAAC
GATATTCAAGAGATATCGTTGAACTGGATCTCTTTTTTG-39,
and 59-AATTCAAAAAAGAGATCCAGTTCAACGATATCTCTTGAA
TATCGTTGAACTGGATCTCCA-39). GCaMP6f (Addgene 72303)
and mRuby3 (Addgene 74252) were amplified by PCR and ligated
into BamHI and EcoRI restriction sites of FCIV lentiviral vector
(Araki et al., 2004) using homologous recombination-based





GTACAGCTCGTCCAT-39). MLKL.ND (Human ORF Library, Clo-
neID: TOLH-1510032, Tissue Culture Support Center, Washington
University in St. Louis) were amplified by PCR and ligated into
BsiWI and EcoRI restriction sites of FCIV-FkbpF36V-TIR (Gerdts et




HEK293T cells were used for lentivirus production (Araki
et al., 2004). Cells were seeded at 70–80% confluency per 35-
mm well the day before transfection. FCIV or shRNA lentivirus
constructs (1.2 µg) were cotransfected with vesicular stomatitis
virus - G (600 ng) and pSPAX2 (800 ng) using FuGENE 6
(Promega). The lentiviral supernatants were collected at 2 d
after transfection, and then the cleared supernatant was con-
centrated with Lenti-X Concentrator (Clontech) to a final con-
centration of 1–10 × 107 particles/ml. Lentivirus transduction
efficiency was monitored with tagged fluorophore and is ∼100%
in DRG neurons. There is no difference in expression level be-
tween WT and SARM1 KO DRG neurons.
Live-cell imaging of axonal calcium
DRG neurons were cultured in a FluoroDish (WPI) that has a
glass bottom, allowing for use of an objective lens with im-
mersion oil for GCaMP6 calcium imaging. At DIV2, lentivirus
expressing GCaMP6 for calcium and mRuby3 for axon integrity
were transduced to cultured DRG neurons. To maintain 37°C
temperature, and 100 ml/min 5% CO2/95% airflow rate during
imaging, a Chamlide TC (Live Cell Instrument) was connected to
a Leica DMI4000Bmicroscope under confocal settings using 20×
oil immersion objectives (NA 0.6) and Leica DFC7000 T 2.8 MP
Color Microscope Camera at RT. The Leica Application Suite X is
the software platform to acquire and analyze images. Optical
sectioning and laser settings were kept constant across all image
data acquisition sessions. Images for GCaMP6 and mRuby3 were
acquired every 30 or 60min until the end of the imaging session.
Immunohistochemistry
Retina and optic nerves were fixed with 4% PFA for 2 h at RT.
Blocking solution was made with PBS including 10% normal goat
serum and 0.3% TX-100. The primary and secondary antibodies
were diluted in blocking solution and incubated at 4°C for
overnight. Antibodies include mouse anti-Brn3a (1:100, Santa
Cruz, Sc-8429), rabbit anti-Iba1 (1:1,000, Wako, 019–19741),
mouse anti-CC1 (1:500, Millipore Sigma-Aldrich, OP80), and
mouse (BioLegend, 801202) or rabbit (Millipore Sigma-Aldrich,
T3952) anti-TUJ1 (1:1,000). The following day, Alexa Fluor–
conjugated secondary antibodies were incubated for 2 h at RT
(Table S1). Tissue samples were mounted in Vectashield (with
DAPI) for visualization with a Leica DMI4000B microscope
under confocal settings. For the 16-µm tissue sections of retina
or optic nerve (Fig. S1), a cryostat (Leica CM1860) was used.
Western blot analysis
Lysate buffers contain protease (cOmplete, mini, EDTA-free
protease inhibitor cocktail) and phosphatase inhibitor (Phos-
STOP). The lysate buffers were preferentially selected for dif-
ferent proteins. While radioimmunoprecipitation assay buffer
was preferentially used for detecting MLKL and phosphorylated
MLKL proteins, Laemmli buffer was specifically used for de-
tecting NMNAT2 and SCG10. Other proteins have no preference.
Lysates were precleared of debris by centrifugation at 10,000 g
in a refrigerated microcentrifuge for 10 min. Supernatants were
mixed with 5% 2-mercaptoethanol (Millipore Sigma-Aldrich)
and then boiled for 10min. Finally, clarified extracts weremixed
with Laemmli buffer (60 mMTris-HCl, pH 6.8, 50% glycerol, 2%
SDS, and 0.1% bromophenol blue) and analyzed by SDS/PAGE
andWestern blotting. TBS-T (TBS and 0.2% Tween 20) was used
to wash immunoblots in all procedures. For blocking buffers, 5%
milk was commonly added to TBS-T. However, for detecting
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phosphorylated MLKL proteins, 5% BSA was specifically used
instead of milk. After 1 h block at RT, the membrane was incu-
bated overnight with primary antibody. Primary antibodies
were diluted in the blocking buffer as follows: rabbit anti-
pMLKL (1:1,000, S345, Abcam, Ab196436), rabbit anti-MLKL
(1:500, abcepta, AP14272B), rabbit anti-RIP3 (1:500, Abcam,
ab56164), rabbit anti-pRIP3 (T231/S232, 1:500, Cell Signaling,
57220), mouse anti-TUJ1 (1:1,000, BioLegend, 801202), rabbit
anti-caspase 3 (1:1,000, Cell Signaling, 9962), rabbit anti-cleaved
caspase 3 (1:500, Cell Signaling, 9661), mouse anti-NMNAT2
(1:100, Santa Cruz, Sc-515206), and rabbit anti-SCG10 (1:2,000,
Proteintech Group). The following day, HRP-conjugated anti-
mouse or anti-rabbit secondary antibodies (1:5,000 or 1:10,000,
Jackson ImmunoResearch; 115–035-003 or 111–035-144) were in-
cubated for 1 h. For developing immunoblots, a chemiluminescent
method (Millipore Sigma-Aldrich) was used. TUJ1 was used in all
experiments as a loading control. All data quantification of im-
munoblots was performed with ImageJ.
Optic nerves
3 d after TNF-α or PBS injection, optic nerves were collected and
homogenized with cold radioimmunoprecipitation assay buffer.
Homogenization of optic nerves was repeated three times every
20 min on ice.
Axons from DRG neurons
To acquire axon-only lysates, dense spot cultures were prepared
in 24-well plates. Due to the high density of DRG neurons, half
media changes are made every 3 d to prevent nutrient loss. On
DIV7, a plate was placed first on ice, and thenwashed with a cold
PBS several times. Amicroscalpel was used to remove cell bodies
of DRG neurons (Fig. S8 A and Fig. 5 E). Axon-only lysate was
collected from three or four wells.
Data analysis
Retina and optic nerve
In each experiment, sample number (n) indicates the number of
animals in vivo, and the number of embryos in vitro. At least
five EM pictures per optic nerve were randomly imaged, and
then analyzed/averaged from one animal (Fig. 1, C–E; and Fig. 2
E). To count Brn3a-positive neurons (Fig. 1 G) and Iba1-positive
microglia (Fig. 2 B), three pictures of the retina near optic nerve
head were acquired and analyzed from each animal. For quan-
tification of CC1-positive oligodendrocytes after TNF-α injection
(Fig. 2, D and H), three to four cross-sections (16-µm thickness/
section) of the proximal optic nerve regions were obtained from
a distance of ∼1 mm behind the eye. Those three to four sections
from one optic nerve were analyzed, and then averaged as n = 1.
When counting the number of CC1-positive oligodendrocytes,
the staining that overlaid with nuclear staining was considered
specific.
Axon degeneration
The axon degeneration index (DI) at baseline should be <0.2 to
define intact axons. If baseline measurements were >0.2, we did
not further process experiments as this is an indication of an
unhealthy neuronal culture. In this study, if the axon DI is >0.3
after treatment, then we define those axons as degenerated. As
values increase beyond 0.3, the axons tend to have smaller ax-
onal fragments remaining.
Cell death
To define cell death, we used DAPI (or Hoechst) and EthD (or
propidium iodide [PI]). In general, nuclei of dead cells only stain
for EthD (or PI), and do not stain for DAPI (or Hoechst). The
percentage of cell death is calculated by EthD staining / (EthD
staining + DAPI staining) × 100.
Neuron-specific expression of AAV-SARM1.DN
To confirm that AAV-SARM1.DN is not expressed in oligoden-
drocyte (Fig. S1, C and D), single-section images of four different
channels of a confocal microscope were acquired for the analysis
of pixel intensity. As seen in Fig. S1 C, one line is drawn in a
merged image, and then intensity is measured of each pixel for
four different channels. The intensity of pixels is plotted in Fig.
S1 D. In this example, because the peak of CC1 pixel (red) is far
from the peak of SARM1.DN (green), we are able to define that
SARM1.DN is not expressed in oligodendrocytes.
Statistical analyses
All statistics were performed with GraphPad Prism 8 software.
The Shapiro–Wilk test was used for normality whether or not
data assumed a Gaussian distribution. To determine statistical
significance between groups, unpaired two-way Student’s t test,
one-way ANOVA with post hoc Tukey test, or two-way ANOVA
with post hoc Bonferroni’s multiple comparison test were used
(detailed in figure legends). Statistical significance was noted as
*, P < 0.05; **, P < 0.01; and ***, P < 0.001. All error bars represent
mean ± SEM.
Online supplemental material
Fig. S1 shows that intravitreal injection of AAV-hSyn-
SARM1.DN-EGFP drives expression in RGCs but not oligoden-
drocytes. Fig. S2 shows that cleaved caspase 3 is not detected in
the optic nerve of TNF-α–injected eyes. Fig. S3 shows that
necrostatin-1s does not prevent axon degeneration following
dimerization of MLKL.ND. Fig. S4 shows validation of shRNA for
MLKL in cultured DRG neurons and N2a cells. Fig. S5 shows that
dimerized MLKL.ND requires endogenous MLKL to induce axon
degeneration. Fig. S6 shows that SARM1 KO does not prevent
cell death induced by dimerization of MLKL.ND. Fig. S7 shows
that DLK inhibition and cytoNMNAT1 expression block axon
degeneration induced by dimerization of MLKL.ND. Fig. S8
shows that necroptosis is not activated by or required for Wal-
lerian degeneration. Table S1 shows reagents used in the study.
Video 1 shows that calcium influx by dimerization of MLKL.ND
is completely prevented in axons from SARM1 KO neurons.
Video 2 shows local calcium influx in axons, not in soma by
dimerization of MLKL.ND.
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Supplemental material
Figure S1. Intravitreal injection of AAV-hSyn-SARM1.DN-EGFP drives expression in RGCs but not oligodendrocytes. (A) Representative confocal single
section images of retina (cross-section) following intravitreal injection of AAV-hSyn-SARM1.DN.EGFP. Retina are stained for nuclei (DAPI, blue), axons (TUJ1,
yellow), RGC nuclei (Brn3a, red), and SARM1.DN (green). The white line is the region of interest for the analysis of pixel intensity of each channel. Scale bar, 20
µm. (B) Pixel intensity analysis for the region of interest from A. The RGC nuclear marker Brn3a overlaps with DAPI staining (arrowhead) while the adjacent
GFP signal of SARM1.DN overlaps with TUJ1 (arrow). SARM1.DN is detected in the cytosol of RGCs. (C) Representative confocal single section images of optic
nerve (longitudinal section) following intravitreal injection of AAV-hSyn-SARM1.DN.EGFP. Optic nerve is stained for nuclei (DAPI, blue), axons (TUJ1, yellow),
oligodendrocyte nuclei (CC1, red), and SARM1.DN (green). The white line is the region of interest for the analysis of pixel intensity of each channel. Scale bar, 20
µm. (D) Pixel intensity analysis for the region of interest from A. The mature oligodendrocyte nuclear marker CC1 overlaps with DAPI staining (arrowhead) but
is distant from the axonal staining of SARM1.DN and TUJ1 (arrow) consistent with RGC expression of SARM1.DN. AU, arbitray units; ROI, region of interest.
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Figure S2. Cleaved caspase 3 is not detected in optic nerve of TNF-α injected eyes. Immunoblot of optic nerve (Optic N) extracts stained for caspase-3
(top), cleaved caspase-3 (middle), and TUJ1 (bottom) as a loading control. Samples are collected from optic nerves 3 d after TNF-α or PBS injection (lanes 1–4).
These samples were also used for Fig. 2, I and J. Because cleaved caspse-3 is not detected in TNF-α–injected optic nerves, cultured DRG neurons were in-
cubated with either DMSO (lane 5) or 100 nM bortezomib (BTZ, lane 6) for 18 h as a positive control (Geisler et al., 2019a).
Figure S3. Necrostatin-1s does not prevent axon degeneration following dimerization of MLKL.ND. (A) Representative bright-field and TMRM images
for DRG neurons expressing MLKL.ND 24 h after BB addition. The neurons were treated with either DMSO (control) or necrostatin-1s (Nec-1s) 30 min before
BB addition. Scale bar, 50 µm. (B) Quantitative analysis of axon degeneration at 0 h and 24 h after BB application from bright-field images for neurons treated
with DMSO or the indicated dose of necrostatin-1s. Necrostatin-1s does not block axon degeneration, consistent with MLKL.ND functioning after RIPK1 in the
necroptosis pathway. Axons with a DI >0.3 are defined as degenerated (dashed line). Data represent the mean ± SEM, n = 5; two-way ANOVA with post hoc
Bonferroni’s multiple comparison test; time, F(1, 9) = 257.4, P < 0.0001; interaction, F(9, 9) = 2.513, P = 0.0930; *, P < 0.05; **, P < 0.01; and ***, P < 0.001.
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Figure S4. Validation of shRNA for MLKL in cultured DRG neurons and N2a cells. (A) Immunoblot analysis of MLKL from DRG neurons expressing control
shRNA (shCon) or MLKL targeted shRNA. Arrow (MLKL band), arrowhead (nonspecific band). TUJ1 is used as a loading control. (B) Quantification of MLKL
knockdown in DRG neurons expressing shMLKL as in A. Data represent the mean ± SEM, n = 5; two-tailed unpaired t test, P < 0.0001; *, P < 0.05; **, P < 0.01;
and ***, P < 0.001. (C) Immunoblot analysis of MLKL from N2a cells expressing control or MLKL targeted shRNA. TUJ1 is used as a loading control.
Figure S5. DimerizedMLKL.ND requires endogenousMLKL to induce axon degeneration. (A) Left: Representative bright-field and TMRM images of axons
from DRG neurons expressing MLKL.ND 24 h after BB addition. Neurons express either control or MLKL targeted shRNA. The MLKL shRNA targets the
C-terminal half of MLKL and therefore does not recognize MLKL.ND. Scale bar, 50 µm. Right: Quantitative analysis of axon degeneration at the indicated times
after BB application for the indicted conditions. Axons expressing shRNA to endogenous MLKL are protected for at least 48 h after dimerization of MLKL.ND.
Axons with a DI >0.3 are defined as degenerated (dashed line). Data represent the mean ± SEM, n = 4; two-way ANOVA with post hoc Bonferroni’s multiple
comparison test; time, F(1.116, 6.695) = 159.4; *, P < 0.05; **, P < 0.01; and ***, P < 0.001. (B) Left: Immunoblot of phosphorylated MLKL in lysates from
neurons expressing MLKL.ND collected at 0 or 8 h after BB addition. TUJ1 is used as a loading control. Dimerization of MLKL.ND triggers phosphorylation of
endogenous MLKL. Right: Quantification of phosphorylated MLKL levels normalized to TUJ1. Data represent the mean ± SEM, n = 3; two-tailed unpaired t test,
P = 0.0283; *, P < 0.05; **, P < 0.01; and ***, P < 0.001. (C) Immunoblot analysis as in B but including necrostatin-1s addition where indicated. This experiment
demonstrates that treatment with the RIPK1 inhibitor necrostatin-1s does not prevent the phosphorylation of MLKL induced by dimerization of MLKL.ND.
These data in conjunction with Fig. S3 demonstrate that MLKL.ND does not require upstream RIPK1.
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Figure S6. SARM1 KO does not prevent cell death induced by dimerization of MLKL.ND. (A) Representative bright-field and fluorescent images at 0 or
24 h after BB addition to WT or SARM1 KO DRG neurons that both express MLKL.ND and cytosolic GFP. Cells are stained with EthD (red) and imaged for GFP
(green) to identify dead cells (EthD+ and GFP−). Scale bar, 50 µm. (B)Quantification of cell death of WT and SARM1 KO DRG neurons expressing MLKL.ND with
two different markers for cell death 24 h after BB application. Left: EthD, n = 5; PI, n = 4; Data represent the mean ± SEM; for EthD, two-tailed unpaired t test,
P = 0.34; for PI, two-tailed unpaired t test, P = 0.23.
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Figure S7. DLK inhibition and cytoNMNAT1 expression block axon degeneration induced by dimerization of MLKL.ND. (A) Representative bright-field
and TMRM images of axons from WT DRG neurons expressing MLKL.ND at 24 h after BB treatment. Neurons were pretreated with DMSO or 500 nM DLK
inhibitor (DLKi; GNE-3511). Scale bar, 50 µm. (B) Quantification of axon degeneration at the indicated times after BB (100 nM) application for the conditions
described in A. DLK inhibition blocks axon degeneration for at least 48 h after BB application. Axons with a DI >0.3 are defined as degenerated (dashed line).
Data represent the mean ± SEM, n = 4; two-way ANOVA with post hoc Bonferroni’s multiple comparison test; time, F(1.910, 9.552) = 62.13, P < 0.0001; *, P <
0.05; **, P < 0.01; and ***, P < 0.001. (C) Representative bright-field and EthD fluorescent images of neuronal cell bodies for the conditions described in A at
24 h after BB application. Scale bar, 30 µm. (D) Quantification of neuronal cell death (EthD+) 24 h after BB treatment for the conditions described in A. DLK
inhibitor does not block cell death. Data represent the mean ± SEM, n = 3; two-tailed unpaired t test, P = 0.78. (E) Quantification of axon degeneration in WT
neurons expressing MLKL.ND and infected with lentivirus expressing EGFP (FUGW control) the axon survival factor cytoNMNAT1. Expression of cytoNMNAT1
blocks axon degeneration induced by MLKL.ND dimerization. Axons with a DI >0.3 are defined as degenerated (dashed line). Data represent the mean ± SEM,
n = 5; two-way ANOVAwith post hoc Bonferroni’s multiple comparison test; time, F(1.863, 14.90) = 144.8, P < 0.0001; interaction, F(8, 16) = 4.061, P = 0.0082;
*, P < 0.05; **, P < 0.01; and ***, P < 0.001.
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Video 1. Calcium influx by dimerization of MLKL.ND is completely prevented in axons from SARM1 KO neurons. Live-cell images of WT and SARM1 KO
axons infected with lentivirus encoding GCaMP6 and mRuby3. After BB (100 nM) application, images were acquired every 1 h.
Video 2. Local calcium influx in axons, not in soma by dimerization of MLKL.ND. Live-cell images of WT and SARM1 KO neurons cultured in microfluidic
devices. BB is only applied to the axon compartment. Images were acquired every 1 h.
Table S1 is provided online as a separate file and shows reagents used in the study.
Figure S8. Necroptosis is not activated by nor required for Wallerian degeneration. (A) Schematic diagram of axotomy-induced Wallerian degeneration
in cultured DRG neurons. (B) To assess whether axotomy activates the necroptotic pathway leading to the phosphorylation of MLKL, axon lysates are collected
at 0 and 3 h after axotomy from WT DRG neurons and at 3 h after axotomy from SARM1 KO DRG neurons. 3 h after axotomy was chosen because this is the
time point at which SARM1 is activated and severed axons are committed to degenerate. MLKL is not phosphorylated in response to axon transection. (C) To
determine if necrostatin-1s blocks Wallerian degeneration, WT DRG neurons were treated with 20 µM necrostatin-1s (Nec-1s) 30 min before axon severing.
Axon degeneration was quantified at 0, 9, and 24 h after axotomy. Axons with a DI >0.3 are defined as degenerated (dashed line). Note that necrostatin-1s does
not block degeneration of severed axons. Data represent the mean ± SEM, n = 3; two-way ANOVA with post hoc Bonferroni’s multiple comparison test; time,
F(1.008, 4.031) = 168.9, P = 0.0002; interaction, F(4, 8) = 2.284, P = 0.1488; *, P < 0.05; **, P < 0.01; and ***, P < 0.001. (D) To determine if genetic loss of
MLKL blocksWallerian degeneration, WTDRG neurons were treated with a control or MLKL targeted shRNA as in S4 and S5. Axon degeneration was quantified
at 0, 9, and 24 h after axotomy. Axons with a DI >0.3 are defined as degenerated (dashed line). Knockdown of MLKL does not block degeneration of severed
axons. Data represent the mean ± SEM, n = 4; two-way ANOVA with post hoc Bonferroni’s multiple comparison test; time, F(1.142, 6.854) = 230.8, P < 0.0001;
interaction, F(6, 12) = 5.801, P = 0.0048; *, P < 0.05; **, P < 0.01; and ***, P < 0.001.
Ko et al. Journal of Cell Biology S6




 http://rupress.org/jcb/article-pdf/219/8/e201912047/1046804/jcb_201912047.pdf by W
ashington U
niversity In St. Louis Libraries user on 12 Septem
ber 2020
